Gender Dysphoria Treatment: Therapy, Hormones, and Surgery

Gender dysphoria treatment spans a wide range of interventions, from psychotherapy and social transition to hormone therapy and surgery, and no two treatment paths look exactly alike. The formal diagnosis entered the psychiatric manual (DSM-5) in 2013, replacing the older label “gender identity disorder,” while the World Health Organization moved its own classification out of the mental-health chapter entirely and into a sexual-health chapter in ICD-11. That reclassification was deliberate: the goal was to keep access to medical care while removing the implication that being transgender is itself a disorder. What follows is a walk through the treatment options that exist today, what the evidence says about each one, and where the science remains genuinely uncertain.

How Gender Dysphoria Is Defined and Diagnosed

The current DSM-5 diagnosis of Gender Dysphoria requires a marked incongruence between a person’s experienced gender and the gender assigned at birth, lasting at least six months, paired with clinically significant distress or impairment. The ICD-11 counterpart, Gender Incongruence, drops the distress requirement; a person can receive the diagnosis based on the incongruence alone. Both systems evolved from much earlier classifications. A diagnosis of “transsexualism” first appeared in DSM-III in 1980, and the terminology has been revised in every subsequent edition.¹ The shift toward depathologization has been praised for reducing stigma, though some researchers argue the reclassification was shaped more by advocacy and rights-based frameworks than by new empirical findings about the condition itself.²

In practice, the diagnosis serves a gatekeeping function: it is typically required before insurance will cover hormones or surgery. The tension between making care accessible and maintaining diagnostic rigor is one of the running debates in the field.

Psychotherapy and Mental Health Support

Psychotherapy is often the first professional contact a person with gender dysphoria has, and it serves several roles that are distinct from “treating” the dysphoria itself. A therapist can help someone clarify their gender identity, manage co-occurring depression or anxiety, work through internalized stigma, and plan practical steps like coming out or navigating workplace transition.³ Psychodynamic and exploratory approaches have established track records for a range of mental health conditions and have been applied to gender dysphoria in both youth and adults.⁴

A recent pilot randomized trial tested early-onset “trans-sensitive” therapy offered at the beginning of the gender-affirming process, when people reported the greatest need for self-reflection. Participants who received the therapy showed a meaningful drop in mental distress compared with a control group.⁵ This is a small, early study, but it reinforces the idea that therapy is not an alternative to medical transition so much as a complement that helps people navigate a complex process with better mental health along the way.

Social Transition in Children and Adolescents

Social transition means living in one’s experienced gender in everyday life: using a different name, pronouns, clothing, and presentation without any medical intervention. For children, this is typically the only step taken before puberty. A study of prepubertal transgender children who had socially transitioned found that their rates of depression were no different from those of matched peers or siblings, and their self-worth was comparable, though parents reported somewhat higher anxiety levels.⁶

A larger study comparing the timing of social transition found that transitioning during childhood was not associated with worse mental health outcomes compared with transitioning in adulthood. The picture for adolescent transition was more complicated: initial analyses suggested slightly higher odds of suicidal ideation and lifetime suicide attempts, but those associations disappeared after adjusting for school harassment related to gender identity, suggesting that the distress was driven by how others treated the adolescent rather than by the transition itself.⁷ A systematic review came to a similar split conclusion: studies consistently showed no difference in mental health outcomes for socially transitioned children, but evidence for adolescents was mixed.⁸

Puberty Suppression

GnRH agonists (commonly called “puberty blockers”) pause puberty in adolescents, buying time before irreversible changes occur. The rationale is that stopping unwanted pubertal development reduces distress while the young person and their care team decide on next steps. A small number of longitudinal studies have found meaningful reductions in depressive symptoms and improved overall psychosocial functioning in treated youth.⁹

The trade-offs are real, though. Bone mineral density drops during puberty suppression, particularly at the lumbar spine, and it only partially recovers once sex hormones are introduced. Trans girls appear more vulnerable to this effect than trans boys.¹⁰ A Dutch cohort study tracking bone density from the start of GnRH agonists through long-term hormone therapy found that individuals assigned male at birth still had bone density Z-scores well below average at the lumbar spine even after years of estrogen, while those assigned female at birth mostly recovered to normal ranges on testosterone.¹¹

The effect on brain development is even less well understood. A review of the available literature found that no human study has systematically explored the impact of puberty suppression on neuropsychological function with adequate baseline and follow-up measurement. Some evidence pointed toward a detrimental impact on IQ, but the researchers stressed the need for much better-designed studies before drawing firm conclusions.¹²

Hormone Therapy

For adults and older adolescents, hormone therapy is usually the backbone of medical transition. Testosterone drives masculinizing changes (deeper voice, facial hair growth, body fat redistribution), while estrogen and anti-androgens drive feminizing changes (breast development, skin softening, reduced body hair). Each path carries its own set of risks that need long-term monitoring.

Masculinizing Hormones

The most closely tracked risk of testosterone therapy is erythrocytosis, an increase in red blood cell concentration that can raise the likelihood of blood clots and stroke. In a large Dutch cohort, about one in nine trans men developed a hematocrit above the standard threshold after starting testosterone, and the probability kept climbing over time: roughly 10% after one year and about 38% after a decade.¹³ Smoking, higher body mass, and older age at the start of therapy all raised the odds further. The formulation matters, too: one study found that about a quarter of patients on intramuscular testosterone enanthate developed polycythemia, compared with none on transdermal (patch or gel) testosterone.¹⁴ Routine blood counts are standard practice for anyone on testosterone.

Feminizing Hormones

The headline risk of estrogen therapy is blood clots, both venous (deep vein thrombosis, pulmonary embolism) and arterial. A systematic review and meta-analysis estimated the overall venous clot rate at roughly 2.3 per 1,000 person-years, though significant variation across studies made it difficult to apply that number broadly.¹⁵ The risk is highest in the first year and appears to remain elevated with longer use.¹⁶ Oral estrogen carries a substantially greater clotting risk than transdermal forms, because swallowed estrogen passes through the liver first and triggers more of the proteins involved in clotting. People with additional risk factors like obesity, smoking, a personal or family history of clots, or Factor V Leiden should discuss transdermal options with their provider.¹⁷

Depression and anxiety symptoms tend to decrease after starting hormone therapy. A prospective cohort study found a statistically significant reduction in depression after the first months of treatment, with a smaller, non-significant reduction in anxiety.¹⁸

Surgical Options

Surgery is generally the last step in a treatment pathway and is pursued only by a subset of transgender people. Satisfaction rates are consistently high across studies, but complications vary dramatically depending on the type of procedure.

Top Surgery

Chest masculinization (“top surgery”) is one of the most commonly requested gender-affirming surgeries for trans men and transmasculine individuals. Multiple studies report that quality of life, sexual confidence, and body satisfaction improve significantly afterward, and the vast majority of patients say the surgery had an overall positive impact on their lives.¹⁹ One study found that about nine in ten patients were satisfied or partially satisfied with the overall experience and postoperative result, though satisfaction with unclothed appearance, scarring, and nipple results was lower, each falling around 45-49% “very satisfied.”²⁰ Mental, physical, and social quality-of-life measures were all significantly higher in post-operative groups compared with those still waiting.²¹

Genital Surgery

For trans women, vaginoplasty studies from established centers report high overall satisfaction. One survey of male-to-female patients found that about 87% were satisfied or very satisfied with their outward appearance and about 72% were satisfied or very satisfied with functional outcomes, though the response rate was under 50%, making the numbers less reliable.²²

For trans men, genital surgery is more technically demanding and carries a higher complication burden. Phalloplasty with urethral lengthening (allowing standing urination) had a urethral stricture rate of 63% and a fistula rate of 27% in one follow-up study, with about three-quarters of patients needing revision surgery. After treatment of complications, about 70% could void from the tip of the phallus.²³ Procedures without urethral lengthening have notably lower complication rates, and about 80% of patients in one series reported increased self-esteem.²⁴ These complication realities are a major reason many trans men opt for top surgery alone or choose less complex genital procedures.

Facial Feminization Surgery

Facial feminization surgery (FFS) modifies bony and soft-tissue structures of the face and is pursued by some trans women for whom the face is a primary source of dysphoria or social misgendering. A study comparing patients before and after FFS found independently improved scores across anxiety, depression, social isolation, positive affect, and overall mental health, even after controlling for other surgeries and hormone therapy duration.²⁵ A separate retrospective review found that mental health service use dropped significantly in the year after FFS compared with the year before.²⁶

Fertility Preservation

Both hormone therapy and surgery can impair or eliminate the ability to have biological children. Guidelines recommend that all patients be counseled on fertility preservation options before starting medical or surgical transition, yet this appears to happen inconsistently in practice.²⁷ For trans women, sperm banking before estrogen therapy is straightforward and widely available. For trans men, egg or embryo freezing is the standard option, though the process involves ovarian stimulation and egg retrieval, which some find distressing because of the gendered nature of the procedure.²⁸ The earlier in transition a person addresses this, the more options remain open.

Suicidality and the Limits of the Evidence

One of the most charged questions in this field is whether gender-affirming treatment reduces suicide risk. A review found that rates of suicidal ideation dropped from about 73% to 43% after the initiation of gender-affirming treatments, and rates of suicide attempts dropped from about 36% to 9%.²⁹ That is a large shift, but the studies behind it are largely observational, and separating the effect of treatment from the effect of social support, aging, or self-selection is extremely difficult.

Complicating matters, a database study comparing people who had undergone gender-affirming surgery with control groups found that the surgical group had a roughly 12-fold higher rate of suicide attempts than the general non-surgical population, and about a 5-fold higher rate even after propensity matching with control groups who had unrelated surgeries.³⁰ This does not mean surgery causes suicidality; it likely reflects the fact that people who seek surgery are starting from a much higher baseline of distress than the general population. But it does indicate that surgery alone is not sufficient to close the mental health gap, and ongoing psychiatric care matters.

Detransition

Detransition, in which a person reverts to living as their birth-assigned gender after having socially or medically transitioned, is a topic that generates intense discussion. The reported rates depend heavily on how you define and measure it. A U.S. military healthcare study found that the four-year continuation rate for gender-affirming hormones was about 70%, with 30% discontinuing. Higher discontinuation was associated with transmasculine identity and starting hormones at age 18 or older.³¹ Stopping hormones does not always mean someone has detransitioned in a permanent sense; some people pause for medical reasons, financial barriers, or pregnancy.

Among those who do identify as having detransitioned, the reasons vary. Data from the U.S. Transgender Survey found that about 13% of people who had ever pursued gender affirmation reported a history of detransition, and roughly 82% of those cited external pressures such as family rejection or societal stigma as a driving factor.³² A separate study that specifically recruited people who had stopped identifying as transgender told a different story: in that sample, most cited internal reasons, such as realizing they had confused mental health issues or trauma responses for gender dysphoria, and said detransition was beneficial.³³ The discrepancy probably reflects different populations: one study captured people who still identified as transgender but had temporarily halted their transition, while the other recruited people who had changed their identity entirely. Both patterns exist, and neither should be dismissed.

Non-Binary and Individualized Approaches

Not everyone who experiences gender dysphoria fits a binary male-to-female or female-to-male trajectory. Non-binary individuals may seek partial interventions, like low-dose hormones for subtle changes, top surgery without genital surgery, or voice therapy alone. Research comparing treatment desires in binary and non-binary transgender people found that having a transgender identity does not automatically mean wanting full medical transition, and the authors stressed the need for individualized treatment planning.³⁴ Clinicians increasingly recognize that a one-size approach does not work, and that the menu of available interventions is better thought of as a set of options a person can select from based on their own goals.

Voice Therapy and Other Non-Surgical Treatments

Voice is one of the most persistent sources of social misgendering, particularly for trans women, because estrogen does not reverse the vocal changes caused by testosterone during puberty. Voice training with a speech-language pathologist can raise fundamental frequency and improve how the voice is perceived by listeners. A systematic review and meta-analysis confirmed that speech therapy increased speaking pitch and improved both female voice perception and vocal satisfaction.³⁵ Both traditional weekly sessions and intensive short-course formats produced significant changes in how participants sounded and how satisfied they felt.³⁶

Facial and body hair removal is another area that sounds cosmetic but functions clinically for many trans women. Research has found strong associations between hair removal and reduced gender dysphoria and increased gender euphoria, casting doubt on the characterization of these services as merely cosmetic.³⁷

The Quality of Clinical Guidelines

Two international guidelines, from the World Professional Association for Transgender Health (WPATH) and the Endocrine Society, form the basis of most other national and institutional guidance. A systematic review of pediatric guidelines found that their quality and methodological rigor varied considerably. Few guidelines had systematically reviewed the empirical evidence, and the links between evidence and final recommendations were often unclear.³⁸ A separate review of adult primary-care guidelines reached a similar verdict: scope and presentation were generally clear, but methodological rigor in how the guidelines were actually built was poor.³⁹ This does not mean the recommendations are wrong, but it does mean the field’s evidence base is thinner than many people assume, and clinicians are often working from expert consensus rather than high-quality trials.

Long-Term Health and Aging

Most research on gender-affirming hormone therapy comes from younger populations, and whether those findings hold for people in their fifties, sixties, and beyond is largely unknown.⁴⁰ What is known raises legitimate concerns. Trans women on long-term estrogen face elevated risks of venous clots, heart attack, stroke, and osteoporosis relative to cisgender people. Trans men on long-term testosterone face elevated polycythemia risk and a probable increase in cardiovascular events.⁴¹ Proactive cardiovascular screening and bone-density monitoring become increasingly important with age.

Lifestyle factors compound the medical risks. Transgender individuals as a group have higher rates of smoking, poor nutrition, and sedentary behavior, and minority stress associated with gender dysphoria is thought to be a major driver of those unhealthy patterns.⁴² As the first large cohorts of people who transitioned medically in early adulthood move into middle and older age, the evidence base should finally start catching up with the questions that matter most for long-term care.

What Neuroscience Does and Does Not Tell Us

Brain-imaging research is sometimes invoked to argue that gender dysphoria has a clear biological basis, but the picture is far less tidy than headlines suggest. A mega-analysis combining data from multiple research sites found that transgender individuals differed from cisgender people in certain brain volume and surface-area measures, but the patterns were complex and varied by brain region and measurement type. Rather than falling neatly along a male-female spectrum, transgender brains appeared to present their own distinct profile.⁴³ A systematic review of the broader neuroimaging literature concluded that while some brain features in transgender individuals resemble those of their experienced gender, the majority resemble those of their natal sex, and conflicting results made it hard to identify any features that consistently differ.⁴⁴ Structural connectivity studies add another wrinkle: after controlling for sexual orientation, transgender groups showed sex-atypical white-matter patterns in only two specific brain tracts, while the rest were typical for their birth sex.⁴⁵ The neuroscience is interesting but nowhere near the point where a brain scan could diagnose gender dysphoria, and it should not be used to validate or invalidate anyone’s identity.

1
PubMed. Gender incongruence/gender dysphoria and its classification history ↩︎
2
Journal of Independent Medicine. Diagnostic Neutrality or Sociopolitical Conformity? The Depathologisation of Gender Dysphoria and Gender Incongruence in the DSM and ICD ↩︎
3
Sexologies. Psychotherapy and the real-life experience: From gender dichotomy to gender diversity ↩︎
4
PubMed Central. Psychodynamic psychotherapy for gender dysphoria is not conversion therapy ↩︎
5
PubMed. Early-onset trans-sensitive therapy as part of gender dysphoria care-a pilot randomized controlled trial ↩︎
6
PubMed Central. Mental Health and Self-Worth in Socially Transitioned Transgender Youth ↩︎
7
PubMed Central. Social Transition for Transgender and Gender Diverse Youth, K-12 Harassment, and Adult Mental Health Outcomes ↩︎
8
Archives of Disease in Childhood. Impact of social transition in relation to gender for children and adolescents: a systematic review ↩︎
9
PubMed Central. Consensus Parameter: Research Methodologies to Evaluate Neurodevelopmental Effects of Pubertal Suppression in Transgender Youth ↩︎
10
PubMed Central. Impact of gender-affirming treatment on bone health in transgender and gender diverse youth ↩︎
11
PubMed Central. Bone Mineral Density in Transgender Adolescents Treated With Puberty Suppression and Subsequent Gender-Affirming Hormones ↩︎
12
PubMed. The impact of suppressing puberty on neuropsychological function: A review ↩︎
13
PubMed Central. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years ↩︎
14
PubMed. Prevalence of polycythaemia with different formulations of testosterone therapy in transmasculine individuals ↩︎
15
Clinical Chemistry. Venous Thrombotic Risk in Transgender Women Undergoing Estrogen Therapy: A Systematic Review and Metaanalysis ↩︎
16
PubMed. Thrombotic risk associated with gender-affirming hormone therapy ↩︎
17
Blood. VTE risk in transgender women on estrogen therapy: A review of formulation-specific risks, management strategies, and evidence gaps ↩︎
18
PubMed. Long-term effect of gender-affirming hormone treatment on depression and anxiety symptoms in transgender people: A prospective cohort study ↩︎
19
Plastic & Reconstructive Surgery. Assessing Quality of Life and Patient-Reported Satisfaction with Masculinizing Top Surgery: A Mixed-Methods Descriptive Survey Study ↩︎
20
Transgender Health. High Self-Reported Satisfaction After Top Surgery in Gender-Affirming Surgery: A Single-Center Study ↩︎
21
Journal of Plastic Surgery and Hand Surgery. Top surgery enhances body satisfaction and quality of life in transgender men: results from a cross-sectional study using a transgender-specific questionnaire ↩︎
22
PubMed Central. Satisfaction with male-to-female gender reassignment surgery ↩︎
23
PubMed. Functional Outcomes and Urological Complications after Genital Gender Affirming Surgery with Urethral Lengthening in Transgender Men ↩︎
24
The Journal of Sexual Medicine. Genital Gender-Affirming Surgery Without Urethral Lengthening in Transgender Men—A Clinical Follow-Up Study on the Surgical and Urological Outcomes and Patient Satisfaction ↩︎
25
PubMed. Effect of Gender-affirming Facial Feminization Surgery on Psychosocial Outcomes ↩︎
26
PubMed. Facial Feminization Surgery and Mental Health Resource Utilization: A Retrospective Institutional Review ↩︎
27
PubMed Central. Fertility preservation options for transgender individuals ↩︎
28
PubMed. Fertility preservation options in transgender people: A review ↩︎
29
PubMed Central. Suicide-Related Outcomes Following Gender-Affirming Treatment: A Review ↩︎
30
PubMed Central. Risk of Suicide and Self-Harm Following Gender-Affirmation Surgery ↩︎
31
PubMed Central. Detransition Among Transgender and Gender-Diverse People—An Increasing and Increasingly Complex Phenomenon ↩︎
32
PubMed Central. Factors Leading to “Detransition” Among Transgender and Gender Diverse People in the United States: A Mixed-Methods Analysis ↩︎
33
PubMed Central. Detransition and Desistance Among Previously Trans-Identified Young Adults ↩︎
34
The Journal of Sexual Medicine. Gender Affirming Medical Treatment Desire and Treatment Motives in Binary and Non-Binary Transgender Individuals ↩︎
35
PubMed Central. A speech therapy for transgender women: an updated systematic review and meta-analysis ↩︎
36
PubMed. The Effectiveness of Gender Affirming Voice Training for Transfeminine Clients: A Comparison of Traditional Versus Intensive Delivery Schedules ↩︎
37
PubMed. Hair removal and psychological well-being in transfeminine adults: associations with gender dysphoria and gender euphoria ↩︎
38
Archives of Disease in Childhood. Clinical guidelines for children and adolescents experiencing gender dysphoria or incongruence: a systematic review of guideline quality (part 1) ↩︎
39
PubMed Central. Review and Analysis of International Transgender Adult Primary Care Guidelines ↩︎
40
PubMed Central. Gender-affirming hormone therapy, mental health, and surgical considerations for aging transgender and gender diverse adults ↩︎
41
PubMed. Transgender health and the impact of aging and menopause ↩︎
42
PubMed Central. Getting old in the desired gender: a systematic review on aging diseases in transgender people ↩︎
43
PubMed. The Neuroanatomy of Transgender Identity: Mega-Analytic Findings From the ENIGMA Transgender Persons Working Group ↩︎
44
PubMed Central. Structural, Functional, and Metabolic Brain Differences as a Function of Gender Identity or Sexual Orientation: A Systematic Review of the Human Neuroimaging Literature ↩︎
45
Scientific Reports. Structural connections in the brain in relation to gender identity and sexual orientation ↩︎